CD276 and lung carcinoma: The use of MLN8237 in combination with immunotherapy treatments targeting the PD-1/PD-L1 pathway or B7-H3 pathway should be investigated in in vivo lung cancer models since these combinations may lead to synergistic and more durable anti-tumor effects.